漱玉平民大药房连锁股份有限公司（以下简称"公司"）于2025年6月9日召开第四届董 事会第七次会议，审议通过了《关于提请召开公司2025年第三次临时股东大会的议案》，决 定于2025年6月25日（星期三）14:45以现场表决与网络投票相结合的方式召开公司2025年第 三次临时股东大会，现将本次股东大会的有关事项公告如下： 一、会议基本情况 1、会议届次：2025年第三次临时股东大会 2、会议的召集人：公司董事会 | | | 漱玉平民大药房连锁股份有限公司 关于召开 2025 年第三次临时股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或者重大遗漏。 东只能选择现场表决、网络投票中的一种方式，如果同一表决权出现重复投票表决的，以第 一次有效投票表决结果为准。 6、会议的股权登记日：2025年6月19日（星期四） 7、出席对象： （1）截至2025年6月19日下午收市时，在中国证券登记结算有限责任公司深圳分公司 登记在册的持有公司已发行有表决权股份的公司股东。上述公司全体股东均有权出席本次 股东大会，并可以以书面形式委托代理人出席会议和参加表决，该股东代理人不必 ...

| 证券代码：301017 | 证券简称：漱玉平民 | 公告编号：2025-049 | | --- | --- | --- | | 债券代码：123172 | 债券简称：漱玉转债 | | 漱玉平民大药房连锁股份有限公司 第四届监事会第四次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或者重大遗漏。 监事会认为公司本次部分募投项目结项并将节余募集资金永久补充流动资金，同时注 销募集资金专项账户是公司根据实际经营情况作出的合理决策，有利于提升募集资金使用 效率，不存在变相改变募集资金用途和损害股东利益的情况，有利于公司的长远发展，符合 全体股东的利益；本次事项涉及的审议程序符合相关法律法规的规定。监事会同意公司本 次部分募投项目结项并将节余募集资金永久补充流动资金的相关事项。 表决结果：同意 3 票；反对 0 票；弃权 0 票。 具体内容详见公司同日披露于巨潮资讯网（www.cninfo.com.cn）的《关于向不特定对 象发行可转换公司债券部分募投项目结项并将节余募集资金永久补充流动资金的公告》。 本议案尚需提交股东大会审议。 （二）审议《关于作废部分已授予尚 ...

| 证券代码：301017 | 证券简称：漱玉平民 | 公告编号：2025-048 | | --- | --- | --- | | 债券代码：123172 | 债券简称：漱玉转债 | | 漱玉平民大药房连锁股份有限公司 第四届董事会第七次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或者重大遗漏。 一、董事会会议召开情况 漱玉平民大药房连锁股份有限公司（以下简称"公司"）第四届董事会第七次会议于 2025 年 6 月 9 日在公司会议室以现场结合通讯表决方式召开。会议通知已于 2025 年 6 月 5 日以书面、电子邮件等方式送达各位董事。会议应到董事 9 人，实到董事 9 人，其中董事 隋熠先生、杨策先生，独立董事赵振基先生、李文明先生以通讯表决方式出席。公司监事和 高级管理人员列席了本次会议。会议由董事长李文杰先生主持，本次会议召开符合《中华人 民共和国公司法》及《公司章程》等有关规定。 二、董事会会议审议情况 （一）审议通过《关于向不特定对象发行可转换公司债券部分募投项目结项并将节余 募集资金永久补充流动资金的议案》 董事会同意将公司募投项目"漱玉（枣 ...

Core Viewpoint - The company, Shuyupingmin, is facing a severe crisis marked by a significant loss in its first annual report since going public, the termination of medical insurance agreements, and a notable share sell-off by its founder, raising concerns about its future viability and investor confidence [1][10]. Group 1: Company Performance and Financials - Shuyupingmin reported its first annual loss since its IPO, with a staggering quarterly loss of 176 million yuan, a year-on-year decline of 509.43% [6]. - The company's gross margin has dropped to 27.27%, which is 6 percentage points lower than the industry average, indicating a structural decline in the sales of core products [6]. - The total number of stores decreased by 118 in the past year, with new store openings slowing down to 1,698, a 9.73% reduction from the previous year [6]. - The company's asset-liability ratio surged to 77.16%, with current liabilities reaching 5.595 billion yuan, signaling a critical cash flow situation [7]. Group 2: Regulatory Issues and Market Reactions - The company has faced multiple terminations of medical insurance agreements due to violations, with at least 22 stores in Qingdao losing their insurance qualification this year alone [5]. - A major scandal involving fraudulent insurance claims at one of its stores led to the complete termination of its insurance agreements and criminal investigations, further damaging its reputation [5]. - The founder's decision to sell 3% of her shares for approximately 150 million yuan amid these crises has been interpreted as a lack of confidence in the company's future [10]. - The market has reacted negatively to the company's performance and regulatory issues, with significant share sell-offs from major stakeholders, including Alibaba Health, which sold 4.64 million shares [10].

| 证券代码：301017 | 证券简称：漱玉平民 | 公告编号：2025-047 | | --- | --- | --- | | 债券代码：123172 | 债券简称：漱玉转债 | | 漱玉平民大药房连锁股份有限公司 2025 年 6 月 5 日，公司将部分上述用于暂时补充流动资金的募集资金 5,000.00 万元提 前归还至公司募集资金账户，使用期限未超过 12 个月。同时，公司已将上述募集资金的归 还情况通知了保荐机构及保荐代表人。 截至本公告披露日，公司尚未归还的募集资金金额为 17,000.00 万元，公司将在规定 期限内归还至募集资金专户，并及时履行信息披露义务。 特此公告。 漱玉平民大药房连锁股份有限公司 董 事 会 关于提前归还部分用于暂时补充流动资金的闲置募集资金的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或者重大遗漏。 漱玉平民大药房连锁股份有限公司（以下简称"公司"）于 2024 年 7 月 11 日召开第三 届董事会第三十三次会议和第三届监事会第二十二次会议，分别审议通过了《关于使用部 分闲置募集资金暂时补充流动资金的议案》，同意公司在不 ...

Market Overview - As of 10:30 AM today, the Shanghai Composite Index stands at 3352.43 points, above the six-month moving average, with a change of 0.15% [1] - The total trading volume of A-shares today is 568.946 billion yuan [1] Stocks Performance - A total of 138 A-shares have surpassed the six-month moving average today, with notable stocks showing significant deviation rates [1] - The stocks with the highest deviation rates include: - Dahongli (300865) with a deviation rate of 17.40%, closing at 27.74 yuan, up 19.98% [1] - Huaxi Biological (688363) with a deviation rate of 6.97%, closing at 54.41 yuan, up 7.87% [1] - *ST Chengchang (001270) with a deviation rate of 5.20%, closing at 36.55 yuan, up 5.00% [1] Additional Stocks with Notable Performance - Other stocks with significant performance include: - Zhejiang Shuwenhua (600633) with a deviation rate of 5.17%, closing at 13.62 yuan, up 5.66% [1] - Gehua Cable (600037) with a deviation rate of 4.76%, closing at 7.73 yuan, up 6.47% [1] - Stocks with smaller deviation rates that have just crossed the six-month line include Aotai Biological, Chitianhua, and Emei Mountain A [1]

Core Insights - The article discusses the collaboration between two major pharmaceutical retail companies:漱玉平民大药房 and 大树药局, which is set to launch a new brand called "大树漱玉" in Jinan on June 1 [1][3][10] - This partnership aims to break the traditional single retail model of pharmacies by offering a diverse range of products and services, including health solutions and cross-border goods [3][7][16] Company Overview - 漱玉平民大药房 is a well-established chain in mainland China, ranking among the top ten in the country, while 大树药局 is the leading pharmacy retailer in Taiwan [10][11] - The new brand "大树漱玉" will feature a variety of products beyond traditional pharmaceuticals, including maternal and infant health products, skincare, and medical devices [3][4][7] Market Strategy - The new stores will provide a one-stop shopping experience, allowing consumers to meet various health and wellness needs in one location [6][7] - The collaboration is seen as a response to the increasing competition in the traditional pharmacy sector, where a single product offering is no longer sufficient to capture market share [3][10] Product Offering - "大树漱玉" will include a comprehensive range of maternal and infant products, as well as selected high-quality health items from Japan, South Korea, and globally [4][8] - The introduction of cross-border health products is expected to fill a market gap in Jinan, where such offerings are currently limited [8][10] Industry Trends - The pharmaceutical retail industry is undergoing significant changes, with a shift from traditional drug sales to a focus on health solutions and diversified product offerings [10][16] - The article highlights the trend of integrating pharmacy services with other retail categories, similar to successful models in the US, Japan, and Europe [16][17] Future Plans - Following the launch in Jinan, there are plans to expand the new pharmacy model further into the Shandong province and potentially nationwide [17][18] - The partnership aims to leverage both companies' strengths to create a robust ecosystem that combines pharmaceuticals, health products, and lifestyle goods [16][17]

Group 1 - China Energy Construction won a major coal-fired power project with a bid amount of approximately 14.586 billion yuan, involving six 660 MW supercritical coal-fired generating units and supporting environmental facilities, with a total construction period of about 36.5 months [1] - Taiji Industry plans to repurchase company shares with a total amount not less than 1 billion yuan and not exceeding 1.2 billion yuan, with a maximum repurchase price of 10.38 yuan per share [1] - Youxun Technology won a project from State Grid with a bid amount of approximately 176 million yuan, accounting for 17.44% of the company's audited revenue for 2024 [2] Group 2 - Daili New Materials established an investment fund with a total subscribed capital of 163.3 million yuan, with Daili contributing 10 million yuan, accounting for 6.12% of the fund [4] - Wanyi Technology received a government subsidy of 2.3475 million yuan, which has been confirmed and classified according to relevant accounting standards [6] - Anke Biotech received a drug registration certificate for Acetate Atosiban Injection, which is used for treating preterm labor [7] Group 3 - Renfu Pharmaceutical received a drug registration certificate for Progesterone Soft Capsules, which are used to treat functional disorders caused by progesterone deficiency [9] - Linyang Energy is a recommended candidate for a major contract with State Grid, with a total expected bid amount of approximately 165 million yuan [11] - Hongtian Technology plans to invest 200 million to 300 million yuan to establish a wholly-owned subsidiary in Gansu Province [28] Group 4 - Hunan Xiang Electric received a total of 40 million yuan in government subsidies, which accounts for 16.07% of the company's audited net profit for 2024 [44] - Nengke Technology plans to repurchase shares with a total amount not less than 10 million yuan and not exceeding 20 million yuan, with a maximum repurchase price of 43.00 yuan per share [46] - Xiamen XGMA received 10 million yuan in historical debt repayment, which is expected to increase the company's net profit for 2025 by 3.186 million yuan [48]

| 证券代码：301017 | 证券简称：漱玉平民 | 公告编号：2025-046 | | --- | --- | --- | | 债券代码：123172 | 债券简称：漱玉转债 | | 漱玉平民大药房连锁股份有限公司 关于调剂担保额度暨为子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或者重大遗漏。 一、担保情况概述 漱玉平民大药房连锁股份有限公司（以下简称"公司"）于 2025 年 1 月 21 日召开第 四届董事会第三次会议，于 2025 年 2 月 6 日召开 2025 年第一次临时股东大会，审议通过 了《关于 2025 年度公司及子公司向银行等机构申请综合授信额度及提供担保的议案》，同 意公司及子公司 2025 年度对合并报表范围内各级子公司提供的担保额度为人民币 167,011.00 万元。公司可以根据实际情况，在上述额度范围内，在符合要求的担保对象之 间可以进行担保额度的调剂，担保额度调剂以不跨过资产负债率超过 70%的标准进行调剂。 担保额度有效期自 2025 年第一次临时股东大会审议通过之日起十二个月。具体内容详见公 司于 202 ...

Policy Developments - The National Medical Products Administration (NMPA) announced the conversion of Xiaoer Ganmao Ning Granules and Pugongying Granules from prescription to over-the-counter drugs [1] Drug Approvals - Eisai's lemborexant has been approved by the NMPA for sale in China, targeting adult insomnia, particularly difficulties in falling and maintaining sleep [2] - Rongchang Biologics' injectable Taitasip has received NMPA approval for a new indication to treat generalized myasthenia gravis (gMG) [3] Capital Markets - Chenglian Technology has successfully completed nearly 200 million RMB in B+ round financing, bringing its total financing to over 500 million RMB [4] - Xiantong Pharmaceutical has submitted a listing application to the Hong Kong Stock Exchange, with CICC and CITIC Securities as joint sponsors [5] Industry Collaborations - Drug Ranch has reached an option agreement with Xiamen Tebao Biotech for clinical collaboration on the ALPK1 agonist DF-006 for hepatitis B and liver cancer in Greater China [6] - Chengdu Guowei Biopharmaceutical has signed a new drug research cooperation agreement with Xinlitai, granting exclusive rights for the AGT-siRNA drug GW906 in the Chinese market [8] Market Activity - Paige Biotech has officially listed on the Hong Kong Stock Exchange with an issue price of 15.6 HKD per share, corresponding to a market capitalization of approximately 6.02 billion HKD [7] - The innovative drug sector is experiencing increased activity, with companies actively pursuing technology or commercial rights to accelerate resource integration [9] Corporate Changes - Taiji Group announced the resignation of supervisor Xu Tingmei due to work reasons, which will not affect the normal operation of the supervisory board [10] - Shareholder Qin Guangxia of Shuyuping plans to reduce her stake by up to 3%, amounting to a maximum of 12.07 million shares [11] - Seer Medical announced the transfer of 51% equity in its subsidiary Akesu Yonglin, with part of the transfer payment of 4.2 million RMB still outstanding [12]